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ABSTRACT
Introduction: Combined modality therapy with concurrent chemotherapy and radiation has long been the
standard of care for limited-stage SCLC (LS-SCLC).
However, there is controversy over best combined
modality practices for LS-SCLC. To address these
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controversies, the American Radium Society (ARS)
Thoracic Appropriate Use Criteria (AUC) Committee
have developed updated consensus guidelines for the
treatment of LS-SCLC.
Methods: The ARS AUC are evidence-based guidelines for
speciﬁc clinical conditions that are reviewed by a
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multidisciplinary expert panel. The guidelines include a
review and analysis of current evidence with application of
consensus methodology (modiﬁed Delphi) to rate the
appropriateness of treatments recommended by the panel
for LS-SCLC. Agreement or consensus was deﬁned as less
than or equal to 3 rating points from the panel median. The
consensus ratings and recommendations were then vetted
by the ARS Executive Committee and subject to public
comment before ﬁnalization.
Results: The ARS Thoracic AUC committee developed
multiple consensus recommendations for LS-SCLC. There
was strong consensus that patients with unresectable LSSCLC should receive concurrent chemotherapy with radiation delivered either once or twice daily. For medically
inoperable T1-T2N0 LS-SCLC, either concurrent chemoradiation or stereotactic body radiation followed by adjuvant chemotherapy is a reasonable treatment option. The
panel continues to recommend whole-brain prophylactic
cranial irradiation after response to chemoradiation for LSSCLC. There was panel agreement that prophylactic cranial
irradiation with hippocampal avoidance and programmed
cell death protein-1/programmed death-ligand 1–directed
immune therapy should not be routinely administered
outside the context of clinical trials at this time.
Conclusions: The ARS Thoracic AUC Committee provide
consensus recommendations for LS-SCLC that aim to provide a groundwork for multidisciplinary care and clinical
trials.
 2020 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ARS; AUC; Limited-stage SCLC; Lung cancer

Introduction
SCLC is the second most common thoracic malignancy, representing 10% to 20% of newly diagnosed
lung cancers. Roughly one-third of the cases present in
the limited stage (LS) that is potentially amenable to
curative local therapy.1 Historically, the Veterans Affairs
Lung Study Group deﬁned LS-SCLC as a tumor burden
conﬁned to a hemithorax that could be safely encompassed in a two-dimensional radiation ﬁeld, whereas the
International Association for the Study of Lung Cancer
(IASLC) more recently deﬁned LS-SCLC as nonmetastatic
disease.2 Although the American Joint Committee on
Cancer and IASLC currently endorse a TNM-staging
system for SCLC,3 the vast majority of clinical trials
and evidence-based guidelines have used the LS paradigm to classify patients for eligibility.
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Concurrent chemotherapy with early thoracic radiotherapy (TRT) followed by prophylactic cranial irradiation (PCI) is considered to be the standard of care for
LS-SCLC. However, recent prospective trials have
assessed traditional radiation therapy practices in LSSCLC, such as the necessity for twice-daily radiation,
elective mediastinal irradiation, and PCI. In light of these
recent trial ﬁndings, the American Radium Society (ARS)
reviews the best evidence-based practice for LS-SCLC.

Materials and Methods
The ARS Appropriate Use Criteria (AUC) Executive
Steering Committee selected 15 members for this ARS
Thoracic AUC multidisciplinary expert panel composed of
radiation, medical, and surgical oncologists with subject
matter expertise. An analysis of the medical literature from
peer-reviewed journals of the PubMed database from 1970
to 2019 was conducted to retrieve a comprehensive set of
relevant articles. The search strategy was developed on the
basis of the National Library of Medicine Medical Subject
Headings with addition of subject-speciﬁc keywords.
Owing to the broad scope of medical literature on LS-SCLC,
the thoracic AUC expert panel reviewed pertinent studies
and excluded those that were not relevant or determined
of lower impact or quality. The literature was reviewed and
rated by the multidisciplinary panel for quality of study
design, cohort size, selection bias, evaluation of participants
in relation to time from exposure, and methods of assessments in accordance to the ARS criteria (Supplementary
Appendix). Clinical variants were then developed through
consensus conference calls to address key practice paradigms and controversies in management. A wellestablished methodology (modiﬁed Delphi) was used by
the expert panel to rate the appropriate use of procedures
pertaining to the clinical variants through three rounds of
anonymous voting with monthly conference calls to discuss
rationale to reach consensus. At least 50% attendance was
required for conference call quorum to rate the evidence
and review anonymous voting. Using panel consensus
ﬁndings, an evidence-based AUC consensus document was
generated and approved by the expert panel. Panel
agreement/consensus was deﬁned as ratings falling less
than or equal to 3 points from the group median whereas
disagreement was deﬁned for any group ratings falling
greater than 3 points from the group median. The document was then vetted by the ARS AUC Executive Steering
Committee and returned to the panel with reviewer comments for modiﬁcation. The AUC document was then
subject to a 2-week public comment period before ﬁnalization. Full details on the ARS AUC methodology and other
supporting documents are available at http://www.
americanradiumsociety.org/page/aucmethodology.

---
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Results

3

Oncology Group 9101 suggesting the brain metastasis
rate is roughly 15% to 25%.5,9-11 Furthermore, a National Cancer Database analysis revealed a possible
survival beneﬁt associated with PCI in early stage
SCLC.12 For these reasons, the panel provided a weak
recommendation owing to sparse evidence. One
circumstance in which the panel felt PCI might be
considered more strongly is in patients at risk for being
lost to follow-up.

Early Stage SCLC (T1-T2N0)
Resected T1-T2N0 SCLC. With implementation of lowdose screening chest computed tomography (CT) scans
in patients at high risk for developing lung cancer, the
identiﬁcation of early stage (T1-T2N0) SCLC amenable to
surgical resection is likely to become more common
(Table 1). A large retrospective registry in Japan has
revealed 60% to 70% 5-year overall survival for stage I
SCLC.4 With oncologic resection that includes lobectomy
and adequate mediastinal nodal sampling, there was
panel consensus that adjuvant chemotherapy is recommended to reduce the risk of locoregional and distant
progression and has been evaluated in a single-arm
phase 2 clinical trial, albeit this was not a strong
recommendation given limited strength of evidence.5
The panel strongly felt that adjuvant TRT is usually not
appropriate on the basis of expert consensus unless
there is strong concern for residual disease such as in
cases of close/positive surgical margin or mediastinal
nodal metastases.
The panel evaluated the use of PCI in patients with
early stage LS-SCLC who have underwent surgical
resection followed by adjuvant chemotherapy, but felt
that PCI is controversial, with little prospective evidence
to guide practice.6,7 The panel recognized that although
multiple clinical trials and a meta-analysis have revealed
a reduction in brain metastases and improvement of
survival with PCI,8 these studies included mostly bulky
unresectable disease without brain magnetic resonance
imaging (MRI) screening, and it is unclear whether these
ﬁndings can be extrapolated to surgically resected T1T2N0 SCLC, a population that has a lower rate of brain
metastases compared with more patients with advanced
SCLC. In this population, there are small retrospective
analyses and pattern of failure analysis of Japan Clinical

Deﬁnitive Radiation Therapy for Early Stage T1T2N0 SCLC. In patients with early stage SCLC with
high operative risk or who refuse surgery (Table 2),
deﬁnitive chemoradiation or stereotactic body radiotherapy (SBRT) was evaluated by the committee for
appropriateness. There was strong panel consensus that
concurrent chemoradiation is usually appropriate
because of the inclusion of early stage disease in the
CONVERT (concurrent once-daily versus twice-daily
chemoradiotherapy in patients with limited-stage smallcell lung cancer) trial. In the CONVERT trial, 16.9% of the
patients had stage I to II disease, and those patients had
a median survival of 50 months and 5-year local progression free survival of 47% when treated with concurrent chemoradiation.13 Thus, because patients with
T1-T2N0 SCLC were well represented in the randomized
CONVERT trial, the panel rated this as strong evidence to
support chemoradiation.
The panel evaluated SBRT that has also emerged as a
potential treatment option for T1-T2 SCLC, as ablative
doses of radiation are expected to have high in-ﬁeld tumor control rates.14 Particularly for patients with
medically inoperable cT1-T2N0 SCLC, SBRT can be
considered if positron emission tomography (PET) scan,
brain MRI, and mediastinal staging conﬁrm true early
stage disease. A retrospective multi-institutional analysis
revealed that patients who received consolidative

Table 1. Variant 1
Final Tabulations
Procedure
Adjuvant mediastinal
radiation therapy
Adjuvant cytotoxic
chemotherapy
PCI
Adjuvant anti–PD-L1-directed
immune therapy

Rating
Category

1

2

3

U

3

3

2

A

1

M
U

2

4

5

6

7

4
3

9

1
1

3

8

2
1

7

4

3

Group
Median
Rating

Disagreea

Reference

SQ

SOE

SOR

2

N/A

N/A

EC

[

8

4, 5, 11

3, 2, 3

L

—

6
2

6, 9, 10
N/A

4, 3, 3
N/A

L
L

—
Y

Note: A 60-year-old woman underwent right upper lobectomy with mediastinal nodal dissection revealing a 2 cm SCLC with negative surgical margins. None of
the 15 mediastinal lymph nodes sampled revealed evidence of tumor involvement. SOR: [ strong recommendation; Y weak recommendation; — additional
considerations do not strengthen or weaken the panel’s recommendation.
a
Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the ﬁnal recommendation (see narrative
text). Group median rating is set automatically to 5.
A, usually appropriate; EC, expert consensus; L, limited; M, may be appropriate; N/A, not applicable; PCI, prophylactic cranial irradiation; PD-L1, programmed
death-ligand 1; SOE, strength of evidence; SOR, strength of recommendation; SQ, study quality; U, usually not appropriate.

4 Chun et al

Journal of Thoracic Oncology

Vol.

-

No.

-

Table 2. Variant 2

Procedure
Concurrent thoracic radiation with
platinum/etoposide alone
Deﬁnitive SBRT alone
SBRT followed by consolidative
platinum/etoposide
PCI after chest-directed therapy
and chemotherapy
Consolidative anti–PD-L1-directed
immune therapy after
chest-directed therapy

Final Tabulations
Rating
Category 1 2 3 4 5 6 7

Group
Median
8 9 Rating Disagreea Reference SQ

SOE SOR

A

5

3

1
11

1

M
A

4

6

2
1

M

1

U

2

2
2

4

2

1

13, 37

2, 1

S

[

14, 15
14, 15

3, 3
3, 3

L
L

—
—

6

8

1

EO

—

3

N/A

N/A

L

Y

7
5
7

8

1

X

Note: A 75-year-old man with severe chronic obstructive pulmonary disease is found to have a 1.5 cm right upper lobe SCLC without evidence of mediastinal or
hilar adenopathy by EBUS or PET scan. Because of medical comorbidities, the patient was determined not to be a candidate for surgical resection but he can
tolerate chemotherapy. SOR: [ strong recommendation; Y weak recommendation; — additional considerations do not strengthen or weaken the panel’s
recommendation.
a
Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the ﬁnal recommendation (see narrative
text). Group median rating is set automatically to 5.
A, usually appropriate; EBUS, endobronchial ultrasound; EO, expert opinion; L, limited; M, may be appropriate; N/A, not applicable; PCI, prophylactic cranial
irradiation; PD-L1, programmed death-ligand 1; PET, positron emission tomography; SBRT, stereotactic body radiation therapy; SOE, strength of evidence; SOR,
strength of recommendation; SQ, study quality; U, usually not appropriate.

Executive Summary of evidence-based guideline for
early stage NSCLC with high operative risk.16

chemotherapy after SBRT seem to have superior oncologic outcomes than those who did not for T1-T2 SCLC.15
Although there is no prospective evidence validating the
role of consolidative chemotherapy after SBRT, it can be
considered on the basis of extrapolation from the role of
adjuvant chemotherapy after surgical resection of SCLC.
Similar principles should be considered for PCI in clinical
stage T1-T2 N0M0 disease as discussed previously in
surgically resected disease. The panel strongly recommended that if SBRT is to be delivered, consolidative
chemotherapy is usually appropriate. Our recommendations regarding SBRT for early SCLC are also in line
with the American Society of Radiation Oncology

Locally Advanced SCLC (T3-T4 or Nþ)
Combined Modality Therapy With Concurrent Chemoradiation. The panel strongly endorsed concurrent
platinum doublet chemotherapy with deﬁnitive TRT as
the standard of care for the initial management of locally
advanced LS-SCLC (Table 3).17 In addition to numerous
randomized prospective trials, the beneﬁt of TRT was
veriﬁed by the landmark Pignon et al.18 meta-analysis
that analyzed 13 prospective randomized trials. Despite
a preponderance of evidence supporting the upfront use

Table 3. Variant 3

Procedure
Best supportive care
Systemic platinum/etoposide
chemotherapy alone
Concurrent thoracic radiation
with platinum/etoposide
Thoracic radiation alone
Initiate thoracic radiation by
cycles 1–2 of chemotherapy
Consolidative anti–PD-L1-directed
immune therapy after
chest-directed therapy

Final Tabulations
Group
Median
Rating
Category 1 2 3 4 5 6 7 8 9 Rating Disagreea Reference

SQ

SOE SOR

U
U

7
5

2
3

1

1

A
U
A

3

U

2

3

1

6

2

18
18, 19

3
3, 2

EC
S

[
[

M, 3

2

7

9

17, 18

S

[

4

4

2
8

18
3
L
22, 23, 24,
M, 1, 1, S
25, 26, 27
1, 1, 1
N/A
N/A
L

[
[

2
1

1
1.5

3

Y

Note: A 50-year-old woman is found to have LS unresectable 6 cm right middle lobe SCLC with mediastinal station seven involvement without evidence of
distant metastatic disease (AJCC stage IIIA, cT3N2M0). SOR: [ strong recommendation.
a
Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the ﬁnal recommendation (see narrative
text). Group median rating is set automatically to 5.
A, usually appropriate; AJCC, American Joint Committee on Cancer; EC, expert consensus; L, limited; LS, limited-stage; M, may be appropriate; N/A, not
applicable; PD-L1, programmed death-ligand 1; SOE, strength of evidence; SOR, strength of recommendation; SQ, study quality; U, usually not appropriate.
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of TRT, analyses of the National Cancer Database suggest
that TRT is not utilized in half of LS-SCLC cases in the
United States.19 For these reasons, the panel recommends on the basis of both expert opinion and strong
evidence that best supportive care or systemic therapy
alone is not appropriate. This panel recommendation is
based on studies demonstrating that without incorporation of TRT, nearly all patients progress on chemotherapy and have dismal survival.20 The panel also
reafﬁrmed that the early delivery of TRT is supported by
multiple prospective randomized trials and meta-analysis.21-28 Therefore, the panel strongly recommends that
it is appropriate for TRT to be incorporated with curative intent no later than the second cycle of chemotherapy. Despite limited evidence, the panel strongly
recommended that TRT alone (without chemotherapy) is
not appropriate (unless chemotherapy is medically
contraindicated), as this would likely represent a palliative treatment in a curative setting, and the panel
strongly endorses curative intent when at all feasible for
LS-SCLC.
Although aggressive surgical resection has historically been utilized for LS-SCLC, surgery has fallen out of
favor owing to multiple clinical trials failing to reveal
beneﬁt. Before the introduction of chemotherapy, an
early trial by the Medical Research Council of Great
Britain randomized patients to deﬁnitive surgery versus
radiation for LS-SCLC. The Medical Research Council trial
revealed that radiation had signiﬁcantly better survival
with a median survival of 300 days compared with 199

5

days for surgery (p ¼ 0.04).29 A more modern intergroup trial lead by the Lung Cancer Study Group evaluated the role of trimodality therapy for LS-SCLC,30 in
which patients received induction cyclophosphamide,
doxorubicin, and vincristine chemotherapy and were
randomized to surgery, TRT, and PCI (trimodality)
versus TRT and PCI (bimodality). There were no significant differences in survival between the arms, curbing
enthusiasm for trimodality therapy. For these reasons,
the panel discourages aggressive surgical management
for locally advanced SCLC outside the context of a clinical
trial.
Radiation Dose and Fractionation. One of the most
controversial aspects of combined modality therapy
for LS-SCLC is the optimal radiation and fractionation
for TRT (Table 4). In the trial by Turrisi et al.,31
concurrent cisplatin and etoposide with 45 Gy delivered at 1.8 Gy daily versus 1.5 Gy twice daily revealed
that the twice daily treatment accelerated hyperfractionation and had superior tumor control and
survival.31 The panel recognized that a major criticism
of this trial is that 45 Gy delivered once daily is not
radiobiologically equivalent to 45 Gy delivered twice
daily. With daily fractionation, a number of studies
have used a dose of 60 Gy or more in conjunction with
concurrent chemotherapy, revealing reasonable oncologic outcomes.32,33 To determine the optimal dose, a
phase 1 clinical trial determined that 70 Gy at 2 Gy
once daily and 45 Gy delivered 1.5 Gy twice daily are

Table 4. Variant 4

Procedure
Radiation dose of 45 Gy at
1.5 Gy twice daily
Radiation dose of 60–70 Gy at
1.8–2.0 Gy daily
Radiation concomitant boost
technique to dose of 61.2 Gy
Elective mediastinal nodal irradiation
Motion management (4D CT scan,
breath hold, or abdominal
compression)
IMRT
3D-Conformal radiation therapy
Proton therapy
Daily image guidance (kV or CBCT)

Final Tabulations
Group
Rating
Median
Category 1 2 3 4 5 6 7 8 9 Rating Disagreea Reference

SQ

SOE SOR

A

1 3 5 9

28, 29, 31

1, 3, 2

S

[

A

5 2 2 7

29, 32, 33, 37 3, 2, 2, 1 S

[

2

34

2

L

—

35, 36
N/A

1, 2
N/A

EC
EC

—
[

38
38
39
N/A

2
2
3
N/A

EC
EC
L
EC

[
—
Y
[

M
M
A

A
M
M
A

4 1 3
2 7 1
1

2 1 10
1 1 1 3 5 1

5

5.5
4
3 7

4 1 4 8
6
4.5
6
3 7

Note: A 50-year-old man with LS-SCLC cT4N3M0 is planned to receive concurrent cisplatin/etoposide with thoracic radiation therapy. SOR: [ strong recommendation; Y weak recommendation; — additional considerations do not strengthen or weaken the panel’s recommendation.
a
Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the ﬁnal recommendation (see narrative
text). Group median rating is set automatically to 5.
3D, three dimensional; 4D, four dimensional; A, usually appropriate; CBCT, cone beam CT scan; CT, computed tomography; EC, expert consensus; IMRT, intensity modulated radiation therapy; L, limited; LS, limited-stage; M, may be appropriate; N/A, not applicable; SOE, strength of evidence; SOR, strength of
recommendation; SQ, study quality.
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the maximum tolerated doses with concurrent
chemotherapy.34 Phase 2 data have also revealed
favorable oncologic outcomes with a dose of 70 Gy
delivered daily.35,36 Another strategy to increase radiation dose to tumor has been to use TRT with a
concomitant boost to a dose of 61.2 Gy.37
Two major randomized phase 3 clinical trials, the
landmark European CONVERT trial and the U.S. Trial
CALGB 30610/Radiation Therapy Oncology Group
(RTOG) 0538 have attempted to compare fractionation
schemes for LS-SCLC combined modality therapy. In the
completed phase 3 CONVERT trial, 66 Gy delivered once
daily (median survival of 25 mo) did not have superior
outcomes compared with 45 Gy delivered twice daily
(median survival of 30 mo).38 As CONVERT was not
powered to detect noninferiority, the panel did not feel
that it can be concluded that 66 Gy delivered daily was
equivalent to 45 Gy twice daily. In the ongoing CALGB
30610/RTOG 0538 phase III trial, subjects are being
randomized to either 45 Gy twice daily or 70 Gy daily
(61.2 Gy concomitant boost arm terminated owing to
toxicity analysis). At the 2020 annual meeting of the
American Society of Clinical Oncology, results were
presented in abstract form of a Norwegian randomized
phase 2 trial comparing 60 Gy versus 45 Gy twice daily,
suggesting better survival in the 60 Gy arm (B. H.
Gronberg et al., unpublished data), but the panel decided
to not evaluate this study until ﬁnal publication.
Taken together, the panel concluded that when
feasible, the optimal dose and fractionation for LS-SCLC
is 45 Gy delivered 1.5 Gy twice daily with concurrent
chemotherapy on the basis of strong evidence. In patients for whom twice-daily fractionation is not logistically possible, there was strong panel consensus that a
daily radiation to a dose of 60 to 70 Gy delivered 1.8 to 2
Gy daily fractions is usually appropriate if meeting
acceptable normal tissue constraints such as a maximum
esophageal dose of 66 Gy, volume of normal lung
exposed to 20 Gy less than 35%, and heart volume of
normal lung exposed to 40 Gy less than 30%. As for
concomitant boost technique to a dose of 61.2 Gy for
which there is limited evidence, the panel determined
that it may be appropriate, but ﬁnal results of CALGB
30610/RTOG 0538 are expected to clarify the role of this
fractionation scheme if any.
Thoracic Radiation Technique. The panel also evaluated a number of TRT techniques in variant 4 (Table 4).
Most combined modality studies that validated the role
of radiation for LS-SCLC used two-dimensional techniques that irradiated large volumes of nontarget
normal tissue. However, there is accumulating evidence
supporting the use of technological advancements to
improve tumor target coverage and sparing of nontarget
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organs at risk. Although comparative studies of radiation techniques in LS-SCLC are sparse with little direct
evidence, the panel believes that studies on radiation
techniques in locally advanced NSCLC are directly
applicable to SCLC because of the same anatomical
challenges and normal tissue considerations. Thus,
despite a paucity of evidence, the panel did generate a
number of strong recommendations on the basis of
expert consensus.
For target delineation, the panel recommends patients to undergo PET/CT scan and mediastinal evaluation with endobronchial ultrasound or mediastinoscopy
to generate an accurate gross tumor volume. At the time
of radiation in CT simulation, the panel strongly recommended on the basis of expert consensus that motion
management with either a four-dimensional CT scan,
respiratory gating, breath hold, or abdominal compression is usually appropriate. In developing a clinical target
volume (CTV), reasonable margins are to include 5 to 8
mm beyond the gross tumor volume to account for
occult microscopic disease while respecting anatomical
boundaries. There are several lines of evidence revealing
that elective nodal irradiation (ENI) is unnecessary.
When using PET scans for involved nodal irradiation in
SCLC, a prospective study revealed only a 3% marginal
failure rate.39 Furthermore, in the completed CONVERT
trial that achieved oncologic results as good as or better
than historic controls, ENI was not permitted.40 In the
ongoing CALGB 30610/NRG Oncology RTOG 0538 trial,
the CTV similarly does not include elective mediastinal
nodal stations. On the basis of these rationales, the panel
recommends against including ENI when developing the
CTV in properly staged patients. From the CTV, a planning target volume based on institutional set-up uncertainty should be generated (typically in the range of 5–7
mm with daily image guidance) with radiation dose
prescribed to adequately cover the planning target volume. The panel also strongly recommended that daily
image guidance with kV ﬁlms or cone beam CT scan be
used on the basis of expert consensus.
Although three-dimensional CRT and intensity
modulated radiation therapy (IMRT) have not been
prospectively compared in LS-SCLC, IMRT has been reported to have a lower likelihood of severe pneumonitis
in the deﬁnitive treatment of locally advanced NSCLC.41
As the anatomy and normal tissue constraints are identical for locally advanced NSCLC and LS-SCLC, the panel
strongly recommends that use of IMRT is usually
appropriate on the basis of expert opinion to reduce the
likelihood of severe radiation-related toxicity, recognizing that there is little evidence on technique in SCLC
itself. The panel also determined with a weaker recommendation that three-dimensional CRT may be appropriate depending on clinical urgency and tumor size.

---
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Radiation plan optimization should prioritize maximizing conformity of high-dose regions such as the volume of normal lung exposed to 20 Gy.41 Finally, there
has been interest in using particle therapy for thoracic
malignancies with one encouraging prospective study
reported,42 and further exploration of proton or heavy
ion therapy for is encouraged by the committee.
PCI After Chemoradiation for LS-SCLC. PCI after
thoracic chemoradiation has generally been accepted as
a standard of care for LS-SCLC (Table 5). The metaanalysis of Auperin et al.8 of 17 trials that included
987 patients revealed that PCI not only reduced brain
metastases but was also associated with an absolute
overall survival beneﬁt of 5.4%. Although the premise
of the meta-analysis of Auperin et al.8 was that roughly
50% of patients develop brain metastases, the major
criticism of this assumption is that the included studies
predated the use of MRIs for metastatic work-up.
However, as PCI is a potentially curative modality, the
panel strongly recommends that PCI is usually appropriate on the basis of strong evidence. As for MRI surveillance every 3 months, the panel also felt this to be
an appropriate strategy in lieu of PCI despite limited
evidence. However, the panel felt that observation
without PCI or MRI surveillance is usually not appropriate owing to the high propensity for brain metastases in SCLC.
The optimal dose for PCI has also been a subject of
debate.8 In the trial of Turrisi et al.,31 the PCI dose was
25 Gy delivered in 10 fractions. An international intergroup study evaluated the potential role of dose escalation of PCI.43 In the PCI trial of Le Péchoux et al.,43
patients were randomized to 25 Gy in 10 fractions or
36 Gy delivered either in 2 Gy daily or 1.5 Gy twice daily
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fractions, and 36 Gy unexpectedly neither reduced brain
metastases nor improved survival compared with 25 Gy.
Similarly, the meta-analysis of Auperin et al.8 revealed
that higher PCI doses were not associated with a survival
beneﬁt. Thus, the panel determined that PCI to a dose of
25 Gy delivered in 10 fractions is usually appropriate
and that other dose escalated fractionation schemes are
usually not appropriate.
Although PCI has been revealed to reduce brain metastases and improve survival, it is also associated with
neurocognitive toxicity, and there is ongoing interest in
exploring strategies to reduce such side effects while still
employing radiotherapy to reduce central nervous system failure. An analysis of RTOG 0212 revealed that
more than 60% of patients experienced neurocognitive
deterioration after.44 As the hippocampus is a source of
neural stem cells that are critical for memory and neuroplasticity, the role of hippocampal avoidance using
IMRT for brain metastases and PCI is currently the
subject of the ongoing NRG Oncology Trial CC003.
However, as whole-brain PCI is a potentially curative
modality, the panel recommends that PCI with hippocampal avoidance be offered in the context of a clinical
trial for at this time. The panel felt that IMRT with hippocampal avoidance might be appropriate pending
further study. As blockade of the N-methyl-D-aspartic
acid neurotransmitter receptor with memantine reduces
neurocognitive side effects after whole-brain irradiation,45 the panel rated the use of memantine in
conjunction with PCI to be usually appropriate despite
limited evidence with PCI. In addition, for patients with
history of neurocognitive deﬁcit/disorder, stroke, or
seizure disorder, it is reasonable to defer PCI, in favor of
a surveillance strategy, as such patients were speciﬁcally
excluded from modern PCI trials.43

Table 5. Variant 5

Procedure
Observation without CNS imaging
surveillance
Surveillance MRI of brain every 3 mo
PCI 25 Gy in 10 fractions
PCI 36 Gy at 1.5–2 Gy per fraction
PCI with intensity modulated radiation
for hippocampal avoidance
Administration of memantine with PCI

Final Tabulations
Group
Median
Rating
Category 1 2 3 4 5 6 7 8 9 Rating Disagreea Reference SQ

SOE SOR

U

2 1 6 1

A
A
U
M

1 2 8 1 1 7
1
4 5
7.5
2 1 5 1 1
3
1
1 3 3 1
5

M

2

3

6 2

6

N/A

N/A

EO

—

N/A
8, 28, 40
40, 41
N/A

N/A
EO
M, 1, 1 S
1, 1
S
N/A
L

Y
[
[
Y

42

1

—

L

Note: A 70-year-old man completes concurrent cisplatin/etoposide and thoracic radiation for LS-SCLC. A PET scan 3 months after radiation reveals complete
metabolic response of thoracic disease without distant metastases and an MRI of the brain with contrast reveals no brain metastases. SOR: [ strong
recommendation; Y weak recommendation; — additional considerations do not strengthen or weaken the panel’s recommendation.
a
Disagreement, that is, the variation of the individual ratings from the median rating indicates panel disagreement on the ﬁnal recommendation (see narrative
text). Group median rating is set automatically to 5.
A, usually appropriate; CNS, central nervous system; EO, expert opinion; L, limited; LS, limited-stage; M, may be appropriate; MRI, magnetic resonance
imaging; N/A, not applicable; PCI, prophylactic cranial irradiation; PET, positron emission tomography; S, strong; SOE, strength of evidence; SOR, strength of
recommendation; SQ, study quality; U, usually not appropriate.
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Immune Therapy for LS-SCLC
In addition to concurrent chemoradiation, there is
substantial interest in incorporating programmed cell
death protein-1 and programmed death-ligand 1 (PDL1)–directed immune therapy in the management of LSSCLC (Tables 1–3 and 5). Although the anti–PD-L1
antibody atezolizumab has activity and improves survival in extensive-stage SCLC,46 evidence justifying use of
checkpoint inhibition remains immature. Currently, the
phase 2 randomized STIMULI (small cell lung carcinoma
trial with nivolumab and ipilimumab in limited disease)
trial and another phase 1 trial (NCT02402920) are
evaluating the role of checkpoint inhibitors for LSSCLC,47 and a larger randomized prospective trial is
underway (NRG Oncology LU-005). At this time, the
panel does not recommend the use of immune therapy
outside the context of a prospective clinical trial for
LS-SCLC.

Discussion
The ARS Thoracic AUC have developed consensus
guidelines on appropriate multidisciplinary management
of LS-SCLC. Although the these guidelines are largely in
line with the American Society of Radiation Oncology
and the National Comprehensive Cancer Network,17,48,49
these ARS AUC guidelines provide novel ratings on the
appropriateness of radiation in the context of surgical
management, PCI with hippocampal avoidance, ENI, radiation image guidance, respiratory motion management, radiation dose constraints, IMRT, proton therapy,
and PD-L1–directed immune therapy. As such, these
2020 ARS AUC guidelines for LS-SCLC aim to serve as a
groundwork for multidisciplinary management and
future clinical trials.

Summary of Recommendations
The ARS provides the following conclusions and
summary recommendations for LS-SCLC:
 The panel recommends strongly that adjuvant mediastinal radiation is usually not appropriate for the
typical case with surgically resected pT1-T2N0M0
SCLC with negative margins (variant 1).
 The panel recommends strongly that concurrent
chemotherapy and thoracic radiation are usually
appropriate, and the panel recommends with reservations that SBRT followed by consolidative chemotherapy may be appropriate for the typical case with
medically unresectable early stage SCLC (variant 2).
 The panel recommends strongly that concurrent
chemotherapy and thoracic radiation followed by PCI
are usually appropriate for the typical case with
unresectable node-positive LS-SCLC (variant 3).
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 The panel recommends strongly that radiation therapy
to a dose of 45 Gy at 1.5 Gy twice daily or 60 to 70 Gy
at 1.8 to 2 Gy daily delivered by means of IMRT with
motion management and daily image guidance is
usually appropriate for the typical case with unresectable node-positive LS-SCLC (variant 4).
 The panel recommends strongly that PCI to a dose of
25 Gy delivered in 10 fractions is usually appropriate,
and the panel recommends with reservations that
brain MRI surveillance may be appropriate for the
typical case with LS-SCLC (variant 5).

Summary of Evidence
Of the 47 references cited, there were 14 welldesigned studies (randomized prospective clinical trials), nine moderately well-designed studies, 11 studies
with design limitations, four meta-analyses, eight studies
that were not classiﬁed as primary references, and one
protocol description. These references were published
between 1970 and 2019 (Supplementary Appendix).
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